These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 7015645)

  • 21. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
    Oshaughnessy JA; Blum J; Moiseyenko V; Jones SE; Miles D; Bell D; Rosso R; Mauriac L; Osterwalder B; Burger HU; Laws S
    Ann Oncol; 2001 Sep; 12(9):1247-54. PubMed ID: 11697835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy.
    Hortobagyi GN; Blumenschein GR; Buzdar AU; Yap HY; Schell FC; Barnes BC; Burgess MA
    J Surg Oncol; 1981; 18(2):163-72. PubMed ID: 7300363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
    Moliterni A; Bonadonna G; Valagussa P; Ferrari L; Zambetti M
    J Clin Oncol; 1991 Jul; 9(7):1124-30. PubMed ID: 2045854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
    Martin M; Villar A; Sole-Calvo A; Gonzalez R; Massuti B; Lizon J; Camps C; Carrato A; Casado A; Candel MT; Albanell J; Aranda J; Munarriz B; Campbell J; Diaz-Rubio E;
    Ann Oncol; 2003 Jun; 14(6):833-42. PubMed ID: 12796019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
    J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of five drug combination chemotherapy in the management of recurrent carcinoma of the breast.
    Lee JM; Abeloff MD; Lenhard RE; Baker RR
    Surg Gynecol Obstet; 1974 Jan; 138(1):77-80. PubMed ID: 4809006
    [No Abstract]   [Full Text] [Related]  

  • 27. [Feasibility of a cyclophosphamide methotrexate and 5-fluorouracil regime intravenously administered with and without granulocyte-colony stimulating factor in surgically treated breast carcinoma].
    Garrone O; Del Mastro L; Mariani GL; Ardizzoni A; Venturini M; Rosso R
    Minerva Med; 1993 Sep; 84(9):467-72. PubMed ID: 7504219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808).
    Engelsman E; Klijn JC; Rubens RD; Wildiers J; Beex LV; Nooij MA; Rotmensz N; Sylvester R
    Eur J Cancer; 1991; 27(8):966-70. PubMed ID: 1832904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer.
    Papadimitriou CA; Dimopoulos MA; Ampela C; Louvrou-Fertaki A; Anagnostopoulos A; Athanassiades P; Stamatelopoulos S; Keramopoulos A
    Oncology; 1998; 55(6):533-7. PubMed ID: 9778619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.
    Colleoni M; Litman HJ; Castiglione-Gertsch M; Sauerbrei W; Gelber RD; Bonetti M; Coates AS; Schumacher M; Bastert G; Rudenstam CM; Schmoor C; Lindtner J; Collins J; Thürlimann B; Holmberg SB; Crivellari D; Beyerle C; Neumann RL; Goldhirsch A; ;
    Br J Cancer; 2002 Jun; 86(11):1705-14. PubMed ID: 12087454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.
    Isaac N; Panzarella T; Lau A; Mayers C; Kirkbride P; Tannock IF; Vallis KA
    Cancer; 2002 Aug; 95(4):696-703. PubMed ID: 12209711
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
    Cocconi G; De Lisi V; Boni C; Mori P; Malacarne P; Amadori D; Giovanelli E
    Cancer; 1983 Feb; 51(4):581-8. PubMed ID: 6336981
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
    Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
    J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.
    Ingle JN; Foley JF; Mailliard JA; Krook JE; Hartmann LC; Jung SH; Veeder MH; Gesme DH; Hatfield AK; Goldberg RM
    Cancer; 1994 May; 73(9):2337-43. PubMed ID: 8168039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Kimura M; Tominaga T; Takatsuka Y; Toi M; Abe R; Koyama H; Takashima S; Nomura Y; Miura S; Kimijima I; Tashiro H; Ohashi Y;
    Breast Cancer; 2010 Jul; 17(3):190-8. PubMed ID: 19575284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.
    Jodrell DI; Smith IE; Mansi JL; Pearson MC; Walsh G; Ashley S; Sinnett HD; McKinna JA
    Br J Cancer; 1991 May; 63(5):794-8. PubMed ID: 2039705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.
    Baldini E; Gardin G; Giannessi PG; Evangelista G; Roncella M; Prochilo T; Collecchi P; Rosso R; Lionetto R; Bruzzi P; Mosca F; Conte PF
    Ann Oncol; 2003 Feb; 14(2):227-32. PubMed ID: 12562649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.